• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baricitinib therapy in critical COVID-19: plenty of promise, but no hard evidence yet.

作者信息

You Seung-Hun, Baek Moon Seong, Kim Tae Wan, Jung Sun-Young, Kim Won-Young

机构信息

Department of Global Innovative Drugs, The Graduate School of Chung-Ang University, Chung-Ang University, Seoul, Republic of Korea.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.

出版信息

Crit Care. 2024 Dec 18;28(1):409. doi: 10.1186/s13054-024-05191-9.

DOI:10.1186/s13054-024-05191-9
PMID:39696464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11654440/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9dd/11654440/657581a5016a/13054_2024_5191_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9dd/11654440/657581a5016a/13054_2024_5191_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b9dd/11654440/657581a5016a/13054_2024_5191_Fig1_HTML.jpg

相似文献

1
Baricitinib therapy in critical COVID-19: plenty of promise, but no hard evidence yet.巴瑞替尼治疗重症新型冠状病毒肺炎：前景广阔，但尚无确凿证据。
Crit Care. 2024 Dec 18;28(1):409. doi: 10.1186/s13054-024-05191-9.
2
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.巴瑞替尼治疗住院成人严重或危重症 COVID-19 的疗效和安全性（Bari-SolidAct）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8.
3
Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19.COVID-19 患者体内连续静脉-静脉血液透析时巴利昔替尼的药代动力学和透析清除率。
Int J Antimicrob Agents. 2023 Sep;62(3):106920. doi: 10.1016/j.ijantimicag.2023.106920. Epub 2023 Jul 11.
4
Beta-blockers in patients with septic shock: plenty of promise, but no hard evidence yet.β受体阻滞剂用于感染性休克患者：前景广阔，但尚无确凿证据。
J Thorac Dis. 2016 Sep;8(9):E1041-E1043. doi: 10.21037/jtd.2016.08.52.
5
Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis.巴瑞替尼治疗住院 COVID-19 成人患者的疗效和安全性：系统评价和荟萃分析。
Eur J Med Res. 2023 Nov 21;28(1):536. doi: 10.1186/s40001-023-01403-0.
6
Pharmacokinetics of baricitinib in critically ill COVID-19 patients.巴瑞替尼在重症 COVID-19 患者中的药代动力学。
Clin Biochem. 2023 Aug;118:110601. doi: 10.1016/j.clinbiochem.2023.110601. Epub 2023 Jun 22.
7
Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.巴利昔替尼治疗重症 COVID-19：住院预处理患者的疗效和安全性。
Eur J Hosp Pharm. 2022 Mar;29(e1):e41-e45. doi: 10.1136/ejhpharm-2021-002741. Epub 2021 Jul 28.
8
Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.巴瑞替尼对比托珠单抗治疗重症 COVID-19 患者：一项回顾性队列研究。
Pharmacotherapy. 2024 Jan;44(1):28-38. doi: 10.1002/phar.2867. Epub 2023 Aug 24.
9
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.巴瑞替尼治疗 COVID-19 住院患者的疗效（RECOVERY 研究）：一项随机、对照、开放标签、平台试验及更新的荟萃分析。
Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6.
10
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.巴瑞替尼、瑞德西韦和地塞米松联合治疗 COVID-19 缺氧成人患者的疗效：一项回顾性研究。
Respir Med Res. 2022 May;81:100903. doi: 10.1016/j.resmer.2022.100903. Epub 2022 Mar 19.

引用本文的文献

1
Optimal timing for assessing post-intensive care syndrome in clinical research: a scoping review and expert survey.临床研究中评估重症监护后综合征的最佳时机：一项范围综述和专家调查。
J Intensive Care. 2025 Aug 18;13(1):45. doi: 10.1186/s40560-025-00817-8.

本文引用的文献

1
Commenting on baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.关于巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的比较：一项全国性队列研究
Crit Care. 2024 Nov 5;28(1):357. doi: 10.1186/s13054-024-05116-6.
2
Baricitinib versus tocilizumab in mechanically ventilated patients with COVID-19: a nationwide cohort study.巴瑞替尼与托珠单抗治疗新型冠状病毒肺炎机械通气患者的疗效比较：一项全国性队列研究
Crit Care. 2024 Aug 29;28(1):282. doi: 10.1186/s13054-024-05063-2.
3
Nutrition support for critically ill patients during the COVID-19 pandemic: the Italian SIAARTI survey.
COVID-19大流行期间危重症患者的营养支持：意大利SIAARTI调查
J Anesth Analg Crit Care. 2022 Aug 9;2(1):35. doi: 10.1186/s44158-022-00063-6.
4
Nutrition Therapy by Nutrition Support Team: A Comparison of Multi-Chamber Bag and Customized Parenteral Nutrition in Hospitalized Patients.营养支持团队的营养疗法：多腔袋与定制肠外营养在住院患者中的比较。
Nutrients. 2023 May 29;15(11):2531. doi: 10.3390/nu15112531.
5
Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study.在重症监护的第一周期间出现胃肠道症状与不良预后相关：一项前瞻性多中心研究。
Intensive Care Med. 2013 May;39(5):899-909. doi: 10.1007/s00134-013-2831-1. Epub 2013 Jan 31.